These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
248 related articles for article (PubMed ID: 30255262)
1. [Treatment of central serous chorioretinopathy with mineralocorticoid receptor antagonists]. Cakir B; Agostini H; Lange C Ophthalmologe; 2019 Feb; 116(2):189-200. PubMed ID: 30255262 [TBL] [Abstract][Full Text] [Related]
2. Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy: a pilot study. Bousquet E; Beydoun T; Zhao M; Hassan L; Offret O; Behar-Cohen F Retina; 2013; 33(10):2096-102. PubMed ID: 23719402 [TBL] [Abstract][Full Text] [Related]
3. Clinical experience with eplerenone to treat chronic central serous chorioretinopathy. Cakir B; Fischer F; Ehlken C; Bühler A; Stahl A; Schlunck G; Böhringer D; Agostini H; Lange C Graefes Arch Clin Exp Ophthalmol; 2016 Nov; 254(11):2151-2157. PubMed ID: 27145785 [TBL] [Abstract][Full Text] [Related]
4. Spironolactone in the treatment of central serous chorioretinopathy - a case series. Herold TR; Prause K; Wolf A; Mayer WJ; Ulbig MW Graefes Arch Clin Exp Ophthalmol; 2014 Dec; 252(12):1985-91. PubMed ID: 25138605 [TBL] [Abstract][Full Text] [Related]
5. CENTRAL SEROUS CHORIORETINOPATHY TREATED WITH MINERALOCORTICOID ANTAGONISTS: A ONE-YEAR PILOT STUDY. Ghadiali Q; Jung JJ; Yu S; Patel SN; Yannuzzi LA Retina; 2016 Mar; 36(3):611-8. PubMed ID: 26405766 [TBL] [Abstract][Full Text] [Related]
7. Mineralocorticoid receptor antagonists in chronic central serous chorioretinopathy. Sanhueza A; González R Medwave; 2020 Sep; 20(8):e8036. PubMed ID: 33017387 [TBL] [Abstract][Full Text] [Related]
8. Systemic Mineralocorticoid Antagonists in the Treatment of Central Serous Chorioretinopathy. Yang D; Eliott D Semin Ophthalmol; 2017; 32(1):36-42. PubMed ID: 27929707 [TBL] [Abstract][Full Text] [Related]
9. SPIRONOLACTONE AS A THERAPEUTIC ALTERNATIVE FOR THE BULLOUS VARIANT OF CENTRAL SEROUS CHORIORETINOPATHY. Ramos-Yau EC; Muñoz-Domínguez E; Contreras-Mérida SP; Valencia-Londoño LM Retin Cases Brief Rep; 2020; 14(4):381-385. PubMed ID: 29595560 [TBL] [Abstract][Full Text] [Related]
10. Predictive Factors of Response to Mineralocorticoid Receptor Antagonists in Nonresolving Central Serous Chorioretinopathy. Bousquet E; Dhundass M; Lejoyeux R; Shinojima A; Krivosic V; Mrejen S; Gaudric A; Tadayoni R Am J Ophthalmol; 2019 Feb; 198():80-87. PubMed ID: 30308202 [TBL] [Abstract][Full Text] [Related]
11. Two-year follow-up of mineralocorticoid receptor antagonists for chronic central serous chorioretinopathy. Zola M; Daruich A; Matet A; Mantel I; Behar-Cohen F Br J Ophthalmol; 2019 Aug; 103(8):1184-1189. PubMed ID: 30355720 [TBL] [Abstract][Full Text] [Related]
12. Eplerenone in patients with chronic recurring central serous chorioretinopathy. Leisser C; Hirnschall N; Hackl C; Plasenzotti P; Findl O Eur J Ophthalmol; 2016 Aug; 26(5):479-84. PubMed ID: 26692062 [TBL] [Abstract][Full Text] [Related]
13. The use of eplerenone in therapy-resistant chronic central serous chorioretinopathy. Breukink MB; den Hollander AI; Keunen JE; Boon CJ; Hoyng CB Acta Ophthalmol; 2014 Sep; 92(6):e488-90. PubMed ID: 24698599 [No Abstract] [Full Text] [Related]
14. A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROL PILOT STUDY OF EPLERENONE FOR THE TREATMENT OF CENTRAL SEROUS CHORIORETINOPATHY (ECSELSIOR). Rahimy E; Pitcher JD; Hsu J; Adam MK; Shahlaee A; Samara WA; Vander JF; Kaiser RS; Chiang A; Spirn MJ; Fineman MS Retina; 2018 May; 38(5):962-969. PubMed ID: 28426624 [TBL] [Abstract][Full Text] [Related]
15. SPIRONOLACTONE FOR NONRESOLVING CENTRAL SEROUS CHORIORETINOPATHY: A RANDOMIZED CONTROLLED CROSSOVER STUDY. Bousquet E; Beydoun T; Rothschild PR; Bergin C; Zhao M; Batista R; Brandely ML; Couraud B; Farman N; Gaudric A; Chast F; Behar-Cohen F Retina; 2015 Dec; 35(12):2505-15. PubMed ID: 26017871 [TBL] [Abstract][Full Text] [Related]
16. Spironolactone versus observation in the treatment of acute central serous chorioretinopathy. Sun X; Shuai Y; Fang W; Li J; Ge W; Yuan S; Liu Q Br J Ophthalmol; 2018 Aug; 102(8):1060-1065. PubMed ID: 29089356 [TBL] [Abstract][Full Text] [Related]
17. Mineralocorticoid Receptor Antagonists in Central Serous Chorioretinopathy: A Meta-Analysis of Randomized Controlled Trials. Wang SK; Sun P; Tandias RM; Seto BK; Arroyo JG Ophthalmol Retina; 2019 Feb; 3(2):154-160. PubMed ID: 31014765 [TBL] [Abstract][Full Text] [Related]
18. MINERALOCORTICOID RECEPTOR ANTAGONIST TREATMENT IN BILATERAL CHRONIC CENTRAL SEROUS CHORIORETINOPATHY: A COMPARATIVE STUDY OF EXUDATIVE AND NONEXUDATIVE FELLOW EYES. Gergely R; Kovács I; Schneider M; Resch M; Papp A; Récsán Z; Nagy ZZ; Ecsedy M Retina; 2017 Jun; 37(6):1084-1091. PubMed ID: 27627749 [TBL] [Abstract][Full Text] [Related]
19. Mineralocorticoid Antagonists in the Treatment of Central Serous Chorioretinopathy: A Comparative Analysis. Kapoor KG; Wagner AL Ophthalmic Res; 2016; 56(1):17-22. PubMed ID: 26982318 [TBL] [Abstract][Full Text] [Related]
20. Comparison of two mineralcorticosteroids receptor antagonists for the treatment of central serous chorioretinopathy. Pichi F; Carrai P; Ciardella A; Behar-Cohen F; Nucci P; Int Ophthalmol; 2017 Oct; 37(5):1115-1125. PubMed ID: 27757733 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]